CT Financial Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

CT Financial Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-45	Closed	-$5.83K	–	671
2016 Q2	$5.83K	Hold	45	–	–	﹤0.01%	489
2016 Q1	$4.21K	Hold	45	–	–	﹤0.01%	522
2015 Q4	$9.12K	Hold	45	–	–	0.01%	463
2015 Q3	$6.54K	Hold	45	–	–	﹤0.01%	502
2015 Q2	$9.57K	Buy	45 +15	+50%	+$3.68K	0.01%	477
2015 Q1	$7.39K	Buy	+30	New	+$7.26K	﹤0.01%	493

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CT Financial Advisors's BLCM Position: Q3 2016 in Review

CT Financial Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2016, closing a stake of 45 shares — an estimated $5.83K sold.

CT Financial Advisors first reported a position in BLCM in Q1 2015 and held it in 6 quarters. The position peaked at $9.57K in Q2 2015. 70 funds tracked by Wall St. Rank hold BLCM as of Q3 2016.

CT Financial Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
CT Financial Advisors sold 45 Bellicum Pharmaceuticals, Inc. shares in Q3 2016, an estimated $5.83K.
CT Financial Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 6 quarters.
CT Financial Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $9.57K in Q2 2015.
70 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2016.

Based on CT Financial Advisors's 13F filing for Q3 2016, filed 12 Oct 2016.